

Prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin

Iwakir R. *Alimentary Pharmacology & Therapeutics*. 2014; 40 (7): 780–795.

- A 24-week, randomized, double-blind, multicentre trial assessed the efficacy and safety of rabeprazole for peptic ulcer recurrence in 452 patients on long-term, low-dose aspirin therapy (81 or 100 mg/day) for cardiovascular or cerebro-vascular protection.
- Rabeprazole (5- and 10 mg) prevented the recurrence of peptic ulcers, and was well tolerated at both doses.

Rabeprazole prevents peptic ulcer recurrence in patients on long-term, low-dose aspirin therapy.